Claims for Patent: 5,508,297

Summary for Patent: 5,508,297

Title:	Vascular hypertrophy suppression treatment
Abstract:	This invention relates to a method for the prophylaxis or treatment of vascular hypertropy in a mammal by administering a pharmaceutically effective amount of a compound represented by the formula (I): ##STR1## wherein ring W is a nitrogen-containing heterocyclic ring residue which may be substituted; R.sup.1 is hydrogen or an optionally substituted hydrocarbon residue which optionally binds through a hetero-atom; R.sup.3 represents a group capable of forming an anion or a group capable of changing thereto; X shows that the phenylene and phenyl groups bind to each other directly or through a spacer having an atomic length of two or less; n denotes 1 or 2; a and b forming the heterocyclic ring residue are independently one or two optionally substituted carbon or hetero atoms; c is an optionally substituted carbon or hetero atom; provided that, when the ring W is a condensed ring, R.sup.1 is hydrogen or an optionally substituted hydrocarbon residue which binds through a hetero atom, or a salt thereof to a mammal in need thereof.
Inventor(s):	Nishikawa; Kohei (Kyoto, JP)
Assignee:	Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:	08/201,122
Patent Claims:	1. A method for the prevention or treatment of vascular hypertrophy in a mammal which comprises administering to said mammal a pharmaceutically effective amount of (.+-.)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylate or a pharmaceutically acceptable salt thereof. 2. A method of claim 1 wherein said vascular hypertrophy occurs after percutaneous transluminal coronary angioplasty. 3. A method of claim 1 wherein said vascular hypertrophy occurs after bypass surgery.